The invention relates to compounds of formula (I)
wherein
one of R
5
and R
6
is hydrogen or R
2
and the other is (a)
pharmaceutical compositions containing them and their use in the treatment of conditions or disorders which are mediated via the S1P1 receptor.
The invention relates to compounds of formula (I)
wherein
one of R5 and R6 is hydrogen or R2 and the other is (a)
pharmaceutical compositions containing them and their use in the treatment of conditions or disorders which are mediated via the S1P1 receptor.